Unknown NA INTERVENTIONAL 2-arm NCT01125020

Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation

Sponsor: Shanghai Changzheng Hospital

Conditions Adjuvant Chemotherapy Hepatocellular Carcinoma Liver Transplantation Survival Tumor Recurrence and Metastasis

Interventions doxorubicin, 5-Fu and cisplatin gemcitabine and oxaliplatin

Updated 4 times since 2017 Last updated: May 17, 2010 Started: Dec 31, 2008 Primary completion: May 31, 2010 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01125020, this NA trial focuses on Adjuvant Chemotherapy and Hepatocellular Carcinoma and remains ongoing. Sponsored by Shanghai Changzheng Hospital, it has been updated 4 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status NA
Jan 2017 — Jan 2021 [monthly]

Unknown Status NA

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Changzheng Hospital
Shanghai Jiao Tong University School of Medicine

Data source: Shanghai Jiao Tong University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China